Pfizer Animal Health has entered into an agreement to acquire multiple product franchises from Schering-Plough Corporation covering all major animal health species including cattle, swine, equine, and companion animal. Terms of the agreement were not disclosed.

Specifically, Pfizer Animal Health would acquire from Schering-Plough a number of animal health products for sale in the European Economic Area covering the categories such as swine E. coli vaccines, equine influenza and tetanus vaccines, ruminant neonatal and clostridia vaccines, rabies vaccines, companion animal veterinary specialty products, parasiticides and anti-inflammatories. The acquisition is subject to certain closing conditions, including antitrust approval.

"The acquisition will enable Pfizer Animal Health Europe to build upon its comprehensive animal health solutions for veterinarians and their clients - farmers and pet owners - in Europe. We look forward to offer veterinarians additional preventative therapies and treatments along with our technical expertise and services to ensure that animals receive the best care possible," said Albert Bourla, president, Pfizer Animal Health, Europe.